Results 81 to 90 of about 38,436 (213)

Cabergoline Use and Pregnancy Outcomes: A Systematic Review

open access: yesBirth Defects Research, Volume 117, Issue 3, March 2025.
ABSTRACT Introduction Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Anne‐Sophie Otis   +4 more
wiley   +1 more source

NEOPLASMS IN ACROMEGALY

open access: yesAlʹmanah Kliničeskoj Mediciny, 2017
Acromegaly is a  rare disease with increased growth hormone secretion most often caused by pituitary adenoma. Not adequately treated acromegaly may lead to early death related to increased rates of acute cardiovascular events, sleep apnea, metabolic ...
I. D. Chikh   +3 more
doaj   +1 more source

Preoperative Noninvasive Radiomics Approach Predicts Tumor Consistency in Patients With Acromegaly: Development and Multicenter Prospective Validation

open access: yesFrontiers in Endocrinology, 2019
Background: Prediction of tumor consistency before surgery is of vital importance to determine individualized therapeutic schemes for patients with acromegaly.
Yanghua Fan   +7 more
semanticscholar   +1 more source

An Unusual Case of 11αB‐Crystallin (CRYAB) Mutation as a Cause of Dilated Cardiomyopathy With Restrictive Physiology: A Case Report and Focused Review of the Literature

open access: yesClinical Case Reports, Volume 13, Issue 3, March 2025.
Mutations in αB‐crystallin (CRYAB) have been related to several diseases. Nevertheless, this mutation is a rare cause that has recently been linked to the onset of dilated cardiomyopathy. We describe a case of CRYAB mutation‐induced dilated cardiomyopathy with restrictive physiology.
Porras Bueno Cristian Orlando   +5 more
wiley   +1 more source

How to Position Pasireotide LAR Treatment in Acromegaly

open access: yesJournal of Clinical Endocrinology and Metabolism, 2019
CONTEXT Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly.
Eva C. Coopmans   +4 more
semanticscholar   +1 more source

EGFR and JAK2 were significant master gene biomarkers in invasive and noninvasive pituitary adenoma

open access: yesPrecision Medical Sciences, Volume 14, Issue 1, Page 4-14, March 2025.
(A) Visualization of the interactions between upregulated and downregulated genes in invasive and non‐invasive pituitary adenomas, highlighting the central role of EGFR and JAK2 as master gene biomarkers. (B) Expression density plots show the distribution of gene expression values after normalization, and volcano plots illustrate significant DEGs ...
Afsaneh Ghasemi   +6 more
wiley   +1 more source

Machine Learning-Based Radiomics Predicts Radiotherapeutic Response in Patients With Acromegaly

open access: yesFrontiers in Endocrinology, 2019
Background: Prediction of radiotherapeutic response before radiotherapy could help determine individual treatment strategies for patients with acromegaly.
Yanghua Fan   +5 more
semanticscholar   +1 more source

Recurrent steroid‐responsive hypertrophic obstructive cardiomyopathy in a Maine Coon cat

open access: yesVeterinary Record Case Reports, Volume 13, Issue 1, March 2025.
Abstract A 5‐year‐old, neutered, female Maine Coon with history of eosinophilic enteritis presented for acute deterioration following placement of a subcutaneous ureteral by‐pass. Physical examination revealed a new 4/6, left, parasternal, systolic heart murmur.
Perrine Henry   +4 more
wiley   +1 more source

Obstructive Sleep Apnea Syndrome in Acromegaly Before and After Treatment

open access: yesTürk Uyku Tıbbı Dergisi, 2014
Introduction Obstructive sleep apnea syndrome (OSAS) prevalence in acromegaly patients is very common compared with general population. It is thought that OSAS in acromegaly patients evolve because of reversible and irreversible anatomical changes ...
Selda Korkmaz   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy